Watch ALXO. Know when insiders buy.
One email the day a filing lands. Free.
ALXO
ALX ONCOLOGY HOLDINGS INC
2.01
−0.02 −0.99%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
53
WATCH · shorts 53
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $277.9MP/E —DIV YIELD —FCF YIELD -25.53%REV TTM —NET INCOME −$80.9MNET CASH $12.5M52W 1.05 – 2.60SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$18M | −$18M | — | -0.13 | −$16.1M | $17K | −$16.1M | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$19M | −$17.9M | — | -0.17 | −$18.6M | $50K | −$18.7M | Aug 6 |
| Q4 2025 · Dec 31derived | — | — | — | −$23M | −$22.8M | — | -0.42 | −$19M | $49K | −$19M | Mar 9 |
| Q3 2025 · Sep 30 | — | — | — | −$22.5M | −$22.1M | — | -0.41 | −$17.1M | $56K | −$17.1M | Nov 7 |
| Q2 2025 · Jun 30 | — | — | — | −$26.6M | −$25.9M | — | -0.49 | −$23.4M | $47K | −$23.5M | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$31.8M | −$30.8M | — | -0.58 | −$24.7M | $60K | −$24.7M | Aug 6 |
| Q4 2024 · Dec 31derived | — | — | — | −$30.6M | −$29.2M | — | -0.53 | −$32M | $60K | −$32.1M | Mar 9 |
| Q3 2024 · Sep 30 | — | — | — | −$32.6M | −$30.7M | — | -0.58 | −$25.4M | $149K | −$25.5M | Nov 7 |
| Q2 2024 · Jun 30 | — | — | — | −$41.5M | −$39.4M | — | -0.76 | −$26.6M | $90K | −$26.7M | Nov 7 |
| Q1 2024 · Mar 31 | — | — | — | −$37.8M | −$35.6M | — | -0.71 | −$37.9M | $148K | −$38.1M | Nov 7 |
| Q4 2023 · Dec 31derived | — | — | — | −$48M | −$45.5M | — | -0.92 | −$39.7M | $148K | −$39.8M | Mar 9 |
| Q3 2023 · Sep 30 | — | — | — | −$53.3M | −$51M | — | -1.24 | −$31.2M | −$1.3M | −$29.9M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$104M | −$101.7M | — | -1.90 | −$84.1M | $212K | −$84.4M | — | — |
| FY2024 · to Dec 31 | — | — | −$142.5M | −$134.8M | — | -2.58 | −$121.9M | $447K | −$122.4M | — | — |
| FY2023 · to Dec 31 | — | — | −$170.3M | −$160.8M | — | -3.74 | −$130.4M | $1.3M | −$131.6M | — | — |
| FY2022 · to Dec 31 | $0 | — | −$127.4M | −$123.5M | — | -3.03 | −$89.2M | $1.4M | −$90.7M | — | — |
| FY2021 · to Dec 31 | $0 | — | −$83.6M | −$83.5M | — | -2.07 | −$68.1M | $666K | −$68.8M | — | — |
| FY2020 · to Dec 31 | $1.2M | — | −$43.7M | −$45.7M | -3869.7% | -2.76 | −$38.3M | $31K | −$38.3M | — | — |
Every number comes from ALX ONCOLOGY HOLDINGS INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.